XML 77 R65.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue Recognition - Additional Information (Detail) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]      
Revenue $ 801,536,000 $ 670,534,000 $ 366,260,000
Revenue Benchmark [Member]      
Disaggregation of Revenue [Line Items]      
Revenue 0    
Revenue Benchmark [Member] | Customer Concentration Risk [Member]      
Disaggregation of Revenue [Line Items]      
Revenue $ 0    
Revenue Benchmark [Member] | Minimum [Member] | Customer Concentration Risk [Member]      
Disaggregation of Revenue [Line Items]      
Concentration Risk, Percentage 10.00%    
Pfizer Inc.      
Disaggregation of Revenue [Line Items]      
Revenue   $ 68,300,000  
Pfizer Inc. | Revenue Benchmark [Member] | Customer Concentration Risk [Member]      
Disaggregation of Revenue [Line Items]      
Concentration Risk, Percentage   10.00% 11.00%
Pfizer Inc. | Revenue Benchmark [Member] | Minimum [Member] | Customer Concentration Risk [Member]      
Disaggregation of Revenue [Line Items]      
Concentration Risk, Percentage   10.00%  
MilliporeSigma      
Disaggregation of Revenue [Line Items]      
Revenue     $ 39,500,000
MilliporeSigma | Revenue Benchmark [Member] | Customer Concentration Risk [Member]      
Disaggregation of Revenue [Line Items]      
Concentration Risk, Percentage     11.00%